CLARITY MEDICAL (01406.HK): Key Findings of Forensic Investigation into IPO Allegations and Independent Internal Control Review; Trading Remains Suspended
- The IPO allegations involved four arrangements, namely the change in remuneration structure from a floating to a fixed monthly basis, allegedly undisclosed loans, the payment and set-off of dividends (involving pre-IPO dividends totalling HK$148,000,000) and the termination of consultancy agreements after the IPO; Grant Thornton was unable to independently verify whether the possible private arrangements existed.
- By reference to the 2022/23 financial year, the Board considered that the findings did not indicate any material adverse impact: revenue of approximately HK$213.8 million (a decrease of approximately 5.1%) and a net loss of approximately HK$3.2 million in that year, with the number of doctors increasing from 11 to 13 and other staff from 111 to 136.
- The internal control review covered nine areas including board governance and decision-making, with the Review Period from 1 April 2025 to 31 March 2026 and the Follow-up Period and Additional Follow-up Period; the Group has implemented all recommended remediation measures.
NewTimeSpace News: On 11 September 2026, Clarity Medical Group Holding Limited (stock code: 01406.HK) announced the key findings of the forensic investigation into the initial public offering (IPO) allegations and the independent internal control review. As regards the IPO allegations, Grant Thornton Consulting Services Limited ("Grant Thornton"), the independent forensic adviser engaged by the Independent Special Committee, has issued an independent forensic investigation report, and the findings of the Grant Thornton Investigation did not provide sufficient evidence that the Group's profitability had been manipulated for the purpose of a false listing.
The announcement stated that the IPO allegations claimed that the prospectus dated 31 January 2022 may have overstated profits and failed to disclose arrangements allegedly involving the redistribution of dividends paid among shareholders to certain former doctors of the Group as remuneration, principally involving four arrangements: the change in remuneration structure from a floating to a fixed monthly basis; undisclosed loans used to compensate for the difference in consultancy fees; the payment and set-off of dividends (involving pre-IPO dividends totalling HK$148,000,000); and the termination of consultancy agreements after the IPO. The Board's view was that the prospectus had disclosed the remuneration adjustments of Dr. Hui and Dr. Liu and the amounts set off through the payment and set-off of dividends; Grant Thornton agreed that the prospectus disclosures were broadly consistent with the records reviewed, and the Board had no reasonable basis to conclude that the prospectus contained any material misstatement or omission. The Board further noted that the findings of the Grant Thornton Investigation did not indicate any material adverse impact on the Group's business operations and financial position; in the 2022/23 financial year, the Group's revenue was approximately HK$213.8 million, a slight decrease of approximately 5.1% from approximately HK$225.2 million in the 2021/22 financial year, and it recorded a net loss of approximately HK$3.2 million, mainly due to an increase of approximately HK$21.7 million in operating expenses (excluding consultancy fees) arising from the expansion and development of its medical centre network.
The announcement further stated that, as regards the internal control review, the Company appointed one of the Big Four advisory firms as its internal control adviser on 26 March 2026, and the internal control adviser submitted the internal control review report to the Board on 11 September 2026, covering board governance and decision-making, related party transactions, integrity and conflict of interest management, regulatory compliance, disclosure and whistleblowing, treasury management, procurement management, contract management, human resources and employment compliance, and financial reporting management; the review covered the Review Period from 1 April 2025 to 31 March 2026, the Follow-up Period from 1 April 2026 to 30 June 2026 and the Additional Follow-up Period from 1 July 2026 to 31 August 2026. Following the internal control adviser's subsequent review, the Group has adopted and implemented all recommended remediation measures. In addition, trading in the shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 15 April 2025 and will continue to be suspended until further notice.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
